Centene’s Recovery Faces a 2027 Margin Test Despite Earnings Gains

Centene raised its 2026 adjusted earnings guidance to more than $4.80 per share, but said roughly 50 cents of this year’s earnings would not recur in 2027. The company’s recovery will need to sustain margin gains to offset that expected shortfall, according to a Zacks analysis published Oct. 7.

Zacks reported that Centene traded at 12.34 times forward earnings, below the industry average of 15.20 times but above its five-year median of 11.33 times. The valuation was also below UnitedHealth’s 17.17 times and Elevance Health’s 13.84 times.

Centene’s Medicaid health benefits ratio, a measure of medical costs relative to premiums, was 93.9% in the second quarter, improving 100 basis points from a year earlier. Management expects a full-year ratio of about 93.5%, slightly better than its original 93.7% outlook.

The company raised its 2026 Marketplace pretax-margin outlook to 4.5% to 5%. But second-quarter results included about $180 million in favorable development tied to 2025 Marketplace risk adjustment, a benefit Zacks said was unlikely to repeat. Membership losses and changing enrollment conditions remain risks.

Analysts expect 2027 earnings of $5.34 per share, while their revenue estimate points to a slight decline to $192.58 billion. As of 17:40 UTC on Oct. 7, Centene shares traded at $65.24, up 0.98% since the previous close.